Drug Discovery and Development

  • Home Drug Discovery and Development
  • Drug Discovery
  • Women in Pharma and Biotech
  • Oncology
  • Neurological Disease
  • Infectious Disease
  • Resources
    • Video features
    • Podcast
    • Voices
    • Webinars
  • Pharma 50
    • 2025 Pharma 50
    • 2024 Pharma 50
    • 2023 Pharma 50
    • 2022 Pharma 50
    • 2021 Pharma 50
  • Advertise
  • SUBSCRIBE

Omics Software

By Drug Discovery Trends Editor | September 17, 2012

Genedata, a leading provider of advanced software solutions for drug discovery and life science research, has released Genedata Expressionist MSX for academic proteomics and metabolomics research. Expressionist MSX offers the same superior algorithms and data visualization capabilities available in the enterprise-level Genedata Expressionist for Mass Spectrometry (MS). Genedata Expressionist for MS is used for high-throughput experiments by leading pharma and crop-science companies. Competitively priced, Expressionist MSX is downloaded directly via the internet and immediately installs for an unmatched user experience in academic research.

Expressionist MSX makes in-depth analysis of complex mass spectrometry experiments affordable and allows scientists to analyze their data with the same rigor, algorithmic power, and high-quality data visualization provided in Genedata’s enterprise solution.

The result of nearly a decade of proven customer success in MS data analysis, Expressionist MSX analyzes proteomics and metabolomics data for a variety of applications directly from the instrument. It downloads from a dedicated website in a Windows-executable file and is up and running in minutes. With native vendor support, Expressionist MSX features built-in, proven statistical tools borrowed from Genedata Expressionist for MS. The validated best-of-breed algorithms in Expressionist MSX significantly reduce the number of false-positive and false-negative biomarkers. Moreover, its powerful and interactive data visualization tools enable researchers to explore and validate MS data and results in completely new ways.

Expressionist MSX is packaged with support for a variety of proteomic and metabolomic MS setups such as

• LC-MS/MS
• SILAC
• MRM
• GC-MS

The system can be applied in a variety of studies including: biomarker discovery and validation; protein profiling; peptide identification and quantification; protein-protein interaction; metabolic profiling within drug development; and plant breeding.

Genedata Expressionist MSX is designed to support academia’s innovative research in mass spectrometry by enabling many new and important applications. Based on proven algorithmic superiority and ease-of-use capabilities of Genedata Expressionist, Expressionist MSX helps scientists to capitalize on the quality and power of enterprise-class software as they open doors to discoveries in the life sciences.

Genedata


Filed Under: Drug Discovery

 

Related Articles Read More >

EVEREST lead investigator on why Dupixent sets a new bar for treating coexisting CRSwNP and asthma
Sanders, King target DTC pharma ads but the industry worries more about threats to its $2B R&D model
Zoliflodacin wins FDA nod for treatment of gonorrhea
FDA approved ENFLONSIA for the prevention of RSV in Infants
“ddd
EXPAND YOUR KNOWLEDGE AND STAY CONNECTED
Get the latest news and trends happening now in the drug discovery and development industry.

MEDTECH 100 INDEX

Medtech 100 logo
Market Summary > Current Price
The MedTech 100 is a financial index calculated using the BIG100 companies covered in Medical Design and Outsourcing.
Drug Discovery and Development
  • MassDevice
  • DeviceTalks
  • Medtech100 Index
  • Medical Design Sourcing
  • Medical Design & Outsourcing
  • Medical Tubing + Extrusion
  • Subscribe to our E-Newsletter
  • Contact Us
  • About Us
  • R&D World
  • Drug Delivery Business News
  • Pharmaceutical Processing World

Copyright © 2025 WTWH Media LLC. All Rights Reserved. The material on this site may not be reproduced, distributed, transmitted, cached or otherwise used, except with the prior written permission of WTWH Media
Privacy Policy | Advertising | About Us

Search Drug Discovery & Development

  • Home Drug Discovery and Development
  • Drug Discovery
  • Women in Pharma and Biotech
  • Oncology
  • Neurological Disease
  • Infectious Disease
  • Resources
    • Video features
    • Podcast
    • Voices
    • Webinars
  • Pharma 50
    • 2025 Pharma 50
    • 2024 Pharma 50
    • 2023 Pharma 50
    • 2022 Pharma 50
    • 2021 Pharma 50
  • Advertise
  • SUBSCRIBE